Clinical Trials Browser

INDUSTRY × Has announcements × Multiple Myeloma × Clear all

NCT04649359 2026-05-19

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Phase 2 Active not recruiting

187 enrolled 14 charts 1 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04634552 2026-05-08

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT05083169 2026-05-08

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 1 FDA

Multiple Myeloma

NCT03319667 2026-05-04

IMROZ

Phase 3 Active not recruiting

475 enrolled 1 FDA

Multiple Myeloma

NCT04246047 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT03761108 2026-04-20

LINKER-MM1

Phase 1/2 Recruiting

387 enrolled 1 FDA

Multiple Myeloma, Recurrence

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 11 charts 1 FDA

Multiple Myeloma

NCT03275285 2026-02-09

IKEMA

Phase 3 Completed

302 enrolled 38 charts 1 FDA

Multiple Myeloma

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

737 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT03525678 2025-09-03

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Phase 2 Completed

221 enrolled 61 charts 1 FDA

Multiple Myeloma

NCT03548207 2025-07-30

CARTITUDE-1

Phase 1/2 Completed

126 enrolled 36 charts 1 FDA

Multiple Myeloma

NCT03158688 2025-05-09

CANDOR

Phase 3 Completed

466 enrolled 33 charts 1 FDA

Multiple Myeloma

NCT03277105 2025-04-29

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

522 enrolled 26 charts 1 FDA

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 2 FDA

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1 Completed

240 enrolled 1 FDA

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

Phase 3 Completed

307 enrolled 32 charts 1 FDA

Multiple Myeloma

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 1 FDA

Multiple Myeloma, Recurrence

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 2 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT02963493 2022-11-22

HORIZON

Phase 2 Completed

157 enrolled 26 charts 1 FDA

Multiple Myeloma